A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1SuspendedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
Solid Tumour
Interventions
DRUG

RO7759065

Specified dose on specified days

DRUG

Atezolizumab

Specified dose on specified days

Trial Locations (11)

2010

St Vincent's Hospital Sydney, Darlinghurst

28027

Clinica Universidad de Navarra-Madrid, Madrid

31008

Clinica Universidad de Navarra, Pamplona

46010

Hospital Clinico Universitario de Valencia, Valencia

91010

City of Hope Comprehensive Cancer Center, Duarte

80045-2517

University of Colorado, Aurora

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

37404-1130

Tennesse Oncology - NASH - SCRI - PPDS, Chattanooga

V5Z 4R2

British Columbia Cancer Agency, Vancouver

M5G 2MR

Princess Margaret Cancer Centre, Toronto

H3T 1E2

Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY